CD200 and neoplasm: While targeting of CD200, TIGIT, and LAG3 is less established in GBM treatment, these targets should be highly considered for future drug development as they appear to be present in GBM and may serve as a strong alternative target should a patient’s tumor express low amounts of PD-1/PD-L1 or CTLA4.